Adaptimmune entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
Combining both companies’ cell therapy leadership and expertise, the collaboration covers two components:
- the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets
- the development of a novel allogeneic personalized cell therapy platform
For each component, Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
“We are proud to partner with Genentech, given their commitment to patients and science in the cancer immunology field. This collaboration broadens Adaptimmune’s leadership position in developing allogeneic cell therapies building on our in-depth knowledge gained from our autologous clinical programs,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Through this collaboration, our platform will form the basis of a personalized allogeneic cell therapy vision, where any patient can receive a T-cell product for their cancer; a significant step towards our goal of making cell therapies both curative and mainstream.”